|
February 22, 2007
Xolair and Black Box Warning
February 16, 2007
Ketek and Restricted Indications
February 5, 2007
Aranesp and Increased Mortality with Off-label Use in Cancer
November 29, 2006
Erythropoiesis-Stimulating Agents and Target Hemoglobin Levels
November 21, 2006
Tamiflu and Altered Behavior
October 24, 2006
Gleevec and Heart Failure
October 5, 2006
Lamictal and Reports of Oral Cleft Cases
September 28, 2006
Avastin and Labeling Changes due to RPLS
September 26, 2006
Ortho Evra and Blood Clots
August 22, 2006
CNS Stimulants for ADHD and Sudden Death
July 27, 2006
Estrogen and Testosterone Associated with Increased Breast Cancer Risk
July 20, 2006
SSRIs/ SNRIs and Triptans Associated with Serotonin Syndrome
July 20, 2006
Aptivus (tipranavir) and Black Box Warning due to Intracranial Hemorrhage
July 6, 2006
Ketek (telithromycin) and liver failure
April 26, 2006
Phenergan (promethazine) and respiratory depression
January 16, 2006
CDC Recommends against use of Amantadine and Rimantadine for the treatment or prophylaxis of influenza
November 22, 2005
FDA MedWatch for Long-acting beta agonists
November 8, 2005
Cymbalta (duloxetine) and hepatotoxicity
October 25, 2005
Cylert (pemoline) market withdrawal
October 17, 2005
2005 Influenza Update
September 30, 2005
Strattera: Black box warning for suicidal thinking in children and adolescents
July 19, 2005
Serious Side Effects from Fentanyl Transdermal Overdoses
July 19, 2005
Palladone Sales and Marketing Suspended
July 19, 2005
FDA Update on Reported Vision Loss with Erectile Dysfunction Agents
April 19, 2005
FDA Public Health Advisory on Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances
April 7, 2005
Bextra Sales and Marketing Suspended
March 24, 2005
Avonex and Hepatic Injury
March 4, 2005
FDA Seizes Avandamet and Paxil CR After Manufacturing Violations
March 4, 2005
Marketing of Tysabri Suspended
February 25, 2005
Advisory Committee Recommends Cox-II's Remain on the Market
February 11, 2005
Adderal XR Sale Suspended In Canada
|
